William Blair initiates Genzyme coverage at outperform

Genzyme Corp. coverage was initiated by William Blair & Co. analyst John Sonnier with an outperform rating, saying the company's established businesses in rare genetic diseases, orthopedics, renal disease, oncology and transplant/immunology has a global and diversified platform that should position the company to achieve long-term earnings growth goal of 20%. Shares of the Cambridge, Mass.-based biotechnology company were up $1.88, or 2.63%, at $73.48 on volume of 4,734,220 shares versus the three-month running average of 2,115,620 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.